Introduction to Pharmacovigilance & ADRs
This foundational unit defines Pharmacovigilance (PV) and traces its historical origin to tragic drug disasters like the Thalidomide catastrophe. It explores the global safety net managed by the WHO and India’s own national PvPI. The core of the unit is dedicated to Adverse Drug Reactions (ADRs)—how to scientifically classify them, determine their severity, and execute formal Causality Assessments to definitively link a drug to a specific toxic event.
Syllabus & Topics
- 1Introduction to Pharmacovigilance: Definition: The science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problem. History: Modern PV was born directly from the Thalidomide tragedy (1961), where a drug prescribed for morning sickness caused profound congenital limb defects (phocomelia) in over 10,000 babies worldwide, exposing the massive flaws in pre-market safety testing.
- 2Global and National PV Programmes: WHO International Drug Monitoring Programme: Established in 1968, headquartered in Uppsala, Sweden (Uppsala Monitoring Centre – UMC). It maintains VigiBase, the world’s largest global database of ADR reports. Pharmacovigilance Program of India (PvPI): Launched in 2010. National Coordinating Centre (NCC) is located at the Indian Pharmacopoeia Commission (IPC), Ghaziabad. Its mission is to safeguard the health of the Indian population by ensuring that the benefits of medicines outweigh the risks.
- 3Introduction to Adverse Drug Reactions (ADRs): Definition: A response to a drug which is noxious and unintended, and which occurs at doses normally used in man for prophylaxis, diagnosis, or therapy. Classification (Rawlins and Thompson): Type A (Augmented): Predictable, dose-dependent, pharmacological extension (e.g., bleeding from heparin). Type B (Bizarre): Unpredictable, dose-independent, immunological/allergic (e.g., anaphylaxis to penicillin). Type C (Chronic): Associated with long-term use (e.g., adrenal suppression by steroids). Type D (Delayed): Carcinogenesis or teratogenesis. Type E (End of Use): Withdrawal syndromes. Type F (Failure): Unexpected failure of therapy.
- 4Detection, Reporting, & Management of ADRs: Reporting: Physicians, pharmacists, and increasingly patients submit Spontaneous Reports via national yellow cards/forms. Management: Withdraw the suspected drug, provide specific antidotes (e.g., naloxone for opioid overdose), provide supportive symptomatic care, and document the event meticulously to prevent future re-challenge.
- 5Methods in Causality Assessment: The systematic evaluation of the likelihood that a particular drug caused a specific adverse event. Scales/Algorithms: (1) Naranjo Probability Scale: A standardized 10-question rubric scoring the event from ‘Definite’ to ‘Doubtful’. (2) WHO-UMC Causality Categories: Classifies ADRs as Certain, Probable, Possible, Unlikely, Conditional, or Unassessable based on clinical-pharmacological aspects of the case history.
- 6Severity, Seriousness, Predictability & Preventability: Severity vs. Seriousness: Severity defines the intensity of the event (mild, moderate, severe). Seriousness is a specific strict regulatory definition. An event is ‘Serious’ ONLY if it: results in death, is life-threatening, requires hospital admission, causes persistent disability, or results in a congenital anomaly. Predictability: Was the ADR expected based on the drug’s known pharmacology? Preventability: Could the ADR have been avoided (e.g., by checking patient allergies or obeying age contraindications) before prescribing?
Learning Objectives
Exam Prep Questions
Q1. What is the difference between an “Adverse Event” (AE) and an “Adverse Drug Reaction” (ADR)?
An Adverse Event (AE) is any undesirable medical occurrence that happens while a patient is taking a drug, regardless of whether the drug caused it. For example, if a patient takes an antibiotic and later experiences an unrelated accident, that event is still recorded as an AE because it occurred during treatment.
An Adverse Drug Reaction (ADR), on the other hand, requires at least a suspected causal relationship between the drug and the reaction. For example, if a patient takes an antibiotic and develops hives or a rash shortly afterward, the drug is suspected to be responsible, making it an ADR.
Q2. Why is the Thalidomide tragedy considered the birth of modern Pharmacovigilance?
Before the Thalidomide tragedy, it was widely believed that the placenta protected the fetus from drugs taken by the mother. However, when thousands of babies were born with severe limb deformities after their mothers used thalidomide for morning sickness in the late 1950s and early 1960s, this assumption was proven dangerously wrong.
This catastrophe forced governments and regulatory authorities worldwide to introduce strict drug safety regulations, including rigorous pre-clinical testing, controlled clinical trials, and continuous post-marketing monitoring of drug safety. These reforms laid the foundation for modern pharmacovigilance systems.
Q3. Why are “Type B” (Bizarre) ADRs considered so dangerous?
Type A (Augmented) reactions are predictable and related to the drug’s pharmacological action. They are usually dose-dependent and can often be managed by adjusting the dosage.
Type B (Bizarre) reactions, however, are unpredictable, not dose-dependent, and unrelated to the normal pharmacological effect of the drug. They often involve immune or genetic mechanisms and can occur even at very small doses. Because they appear suddenly and may cause severe outcomes—such as anaphylactic shock or life-threatening hypersensitivity reactions—they are particularly dangerous and difficult for clinicians to anticipate.